Literature DB >> 26481284

Primary Prevention of Sudden Death in Patients With Valvular Cardiomyopathy.

Moisés Rodríguez-Mañero1, María Teresa Barrio-López2, Emad Abu Assi3, Víctor Expósito-García4, Vicente Bertomeu-González5, Juan Miguel Sánchez-Gómez6, Luis González-Torres7, Ignacio García-Bolao8, Larraitz Gaztañaga9, Pilar Cabanas-Grandío10, José Antonio Iglesias-Bravo11, Álvaro Arce-León12, Ana Andrés la Huerta13, Juan Fernández-Armenta14, Rafael Peinado15, Miguel Angel Arias16, Ernesto Díaz-Infante7.   

Abstract

INTRODUCTION AND
OBJECTIVES: Few data exist on the outcomes of valvular cardiomyopathy patients referred for defibrillator implantation for primary prevention. The aim of the present study was to describe the outcomes of this cardiomyopathy subgroup.
METHODS: This multicenter retrospective study included consecutive patients referred for defibrillator implantation to 15 Spanish centers in 2010 and 2011, and to 3 centers after 1 January 2008.
RESULTS: Of 1174 patients, 73 (6.2%) had valvular cardiomyopathy. These patients had worse functional class, wider QRS, and a history of atrial fibrillation vs patients with ischemic (n=659; 56.1%) or dilated (n=442; 37.6%) cardiomyopathy. During a follow-up of 38.1 ± 21.3 months, 197 patients (16.7%) died, without significant differences among the groups (19.2% in the valvular cardiomyopathy group, 15.8% in the ischemic cardiomyopathy group, and 17.9% in the dilated cardiomyopathy group; P=.2); 136 died of cardiovascular causes (11.6%), without significant differences among the groups (12.3%, 10.5%, and 13.1%, respectively; P=.1). Although there were no differences in the proportion of appropriate defibrillator interventions (13.7%, 17.9%, and 18.8%; P=.4), there was a difference in inappropriate interventions (8.2%, 7.1%, and 12.0%, respectively; P=.03).
CONCLUSIONS: All-cause and cardiovascular mortality in patients with valvular cardiomyopathy were similar to those in other patients referred for defibrillator implantation. They also had similar rates of appropriate interventions. These data suggest that defibrillator implantation in this patient group confers a similar benefit to that obtained by patients with ischemic or dilated cardiomyopathy.
Copyright © 2015 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Appropriate interventions; Desfibrilador automático implantable; Implantable cardioverter-defibrillator; Inappropriate interventions; Intervenciones apropiadas; Intervenciones inapropiadas; Miocardiopatía valvular; Prevención primaria de muerte súbita cardiaca; Primary prevention of sudden cardiac death; Valvular cardiomyopathy

Mesh:

Year:  2015        PMID: 26481284     DOI: 10.1016/j.rec.2015.05.016

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  3 in total

Review 1.  Predictors of mortality and ICD shock therapy in primary prophylactic ICD patients-A systematic review and meta-analysis.

Authors:  Leonard Bergau; Tobias Tichelbäcker; Barbora Kessel; Lars Lüthje; Thomas H Fischer; Tim Friede; Markus Zabel
Journal:  PLoS One       Date:  2017-10-17       Impact factor: 3.240

2.  Long-Term Outcomes Among a Nationwide Cohort of Patients Using an Implantable Cardioverter-Defibrillator: UMBRELLA Study Final Results.

Authors:  Sem Briongos-Figuero; Arcadio García-Alberola; Jerónimo Rubio; José María Segura; Aníbal Rodríguez; Rafael Peinado; Javier Alzueta; José B Martínez-Ferrer; Xavier Viñolas; Joaquín Fernández de la Concha; Ignasi Anguera; María Martín; Laia Cerdá; Luisa Pérez
Journal:  J Am Heart Assoc       Date:  2020-12-25       Impact factor: 5.501

Review 3.  Gender Differences in Appropriate Shocks and Mortality among Patients with Primary Prophylactic Implantable Cardioverter-Defibrillators: Systematic Review and Meta-Analysis.

Authors:  David Conen; Barbora Arendacká; Christian Röver; Leonard Bergau; Pascal Munoz; Sofieke Wijers; Christian Sticherling; Markus Zabel; Tim Friede
Journal:  PLoS One       Date:  2016-09-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.